Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for GILENYA
- Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
- Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke
- Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
- Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).
- Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
- Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
- Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy
- Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
- Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod
- Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
- Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
- A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
- Fingolimod Effect on Cytokine and Chemokine Levels
- Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
- Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya
- Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
- Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
- Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
- Gilenya in Amyotrophic Lateral Sclerosis (ALS)
- Fingolimod in Schizophrenia Patients
- Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
- MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
- ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
- Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
- Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
- The Gilenya Pregnancy Registry
- An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Clinical trials list
click for details